Accolade, Inc.

DB:4NE1 Stock Report

Market Cap: €268.4m

Accolade Valuation

Is 4NE1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4NE1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4NE1 (€3.28) is trading below our estimate of fair value (€51.66)

Significantly Below Fair Value: 4NE1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4NE1?

Key metric: As 4NE1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4NE1. This is calculated by dividing 4NE1's market cap by their current revenue.
What is 4NE1's PS Ratio?
PS Ratio0.6x
SalesUS$441.03m
Market CapUS$275.44m

Price to Sales Ratio vs Peers

How does 4NE1's PS Ratio compare to its peers?

The above table shows the PS ratio for 4NE1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.7x
V3V VITA 34
0.9x3.1%€73.6m
SYAB SYNLAB
0.9x4.4%€2.5b
ILM1 Medios
0.2x4.3%€341.3m
M12 M1 Kliniken
0.9x7.8%€304.3m
4NE1 Accolade
0.6x11.4%€275.4m

Price-To-Sales vs Peers: 4NE1 is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (0.7x).

Price to Sales Ratio vs Industry

How does 4NE1's PS Ratio compare vs other companies in the DE Healthcare Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
EIF MedNation
0.09xn/aUS$4.65m
TLIK Arzneiwerk VIDA
0.07xn/aUS$4.28m
No more companies available in this PS range
4NE1 0.6xIndustry Avg. 0.7xNo. of Companies4PS00.40.81.21.62+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 4NE1 is good value based on its Price-To-Sales Ratio (0.6x) compared to the European Healthcare industry average (0.7x).

Price to Sales Ratio vs Fair Ratio

What is 4NE1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4NE1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.6x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: 4NE1 is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4NE1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€3.28
€6.84
+108.6%
19.1%€9.06€4.77n/a12
Dec ’25€3.52
€6.86
+94.8%
17.3%€8.98€5.05n/a12
Nov ’25€2.88
€6.48
+125.0%
19.1%€8.69€4.57n/a13
Oct ’25€3.42
€7.48
+118.8%
25.7%€11.74€4.82n/a15
Sep ’25€3.86
€7.33
+90.0%
27.4%€11.79€4.54n/a16
Aug ’25€3.76
€7.72
+105.2%
26.2%€12.14€4.67n/a15
Jul ’25€3.30
€7.72
+133.8%
26.2%€12.14€4.67n/a15
Jun ’25€6.60
€12.16
+84.3%
15.4%€14.89€9.31n/a15
May ’25€7.65
€12.44
+62.6%
16.8%€15.86€9.33n/a15
Apr ’25€9.15
€13.89
+51.8%
12.0%€16.59€11.06n/a15
Mar ’25€9.40
€13.89
+47.7%
12.0%€16.59€11.06n/a15
Feb ’25€10.40
€13.80
+32.7%
12.3%€16.56€11.04n/a14
Jan ’25€11.50
€13.55
+17.8%
15.3%€15.59€9.17€3.3613
Dec ’24€7.95
€13.64
+71.5%
14.9%€15.61€9.19€3.5213
Nov ’24€6.05
€14.21
+134.8%
13.6%€16.02€9.42€2.8813
Oct ’24€10.00
€15.45
+54.5%
10.5%€17.79€13.11€3.4213
Sep ’24€12.30
€14.88
+20.9%
10.8%€17.41€12.83€3.8615
Aug ’24€13.50
€14.88
+10.2%
10.8%€17.41€12.83€3.7615
Jul ’24€12.90
€14.88
+15.3%
10.8%€17.41€12.83€3.3015
Jun ’24€11.20
€14.15
+26.3%
10.9%€16.39€11.84€6.6015
May ’24€11.80
€14.10
+19.5%
10.9%€16.34€11.80€7.6515
Apr ’24€12.30
€12.68
+3.1%
13.9%€15.67€9.22€9.1514
Mar ’24€10.30
€12.29
+19.3%
12.0%€13.97€9.32€9.4013
Feb ’24€10.60
€11.87
+12.0%
12.3%€13.65€9.10€10.4013
Jan ’24€7.10
€14.35
+102.1%
14.2%€17.51€10.30€11.5014

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 09:21
End of Day Share Price 2025/01/02 00:00
Earnings2024/08/31
Annual Earnings2024/02/29

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Accolade, Inc. is covered by 23 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew GillmorBaird
Zhilin LongBerenberg
Allen LutzBofA Global Research